Recent Company News

• 09:38 PM ET Nov 03, 2025
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 01:46 PM ET Dec 02, 2025
  

  FDA publishes Untitled Letter sent to Daiichi Sankyo on 24-Nov concerning the promotion of Turalio (¥3714.0000, 0)

• 07:09 AM ET Nov 18, 2025
  

  Follow-up: HLS Therapeutics issues press release on Health Canada approval of NILEMDO for use in Canada and Notice of Non-Compliance for NEXLIZET (C$4.90, 0.00)

• 07:03 AM ET Nov 18, 2025
  

  Esperion partner HLS Therapeutics announces Health Canada approval of NILEMDO for reduction of LDL-cholesterol ($2.82, 0.00)

• 07:05 AM ET Nov 10, 2025
  

  Daiichi Sankyo doses first patient for phase I clinical trial of DS3610 for advanced, metastatic or unresectable solid tumors (¥3305.0000, 0)

• 10:08 PM ET Nov 03, 2025
  

  StreetAccount Summary - Trading higher/lower: Asia mid-morning

• 12:09 AM ET Oct 31, 2025
  

  Daiichi Sankyo reports Q2 net income attributable ¥45.3B vs FactSet ¥89.38B [3 est, ¥83.67-92.48B] (¥3654.0000, -188)

• 10:30 PM ET Oct 30, 2025
  

  Transcript Intelligence: Daiichi Sankyo Q2 Earnings Themes